Testosterone patches charge up older women’s sex
The U.S. Food and Drug Administration (FDA) has granted Selzentry (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination with other antiretrovirals. Selzentry was originally granted accelerated conditional approval in August 2007 based on 24-week data from pivotal Phase 3 studies. Selzentry now becomes the latest fully approved treatment for
Full Post: Selzentry (maraviroc) becomes fully approved HIV antiretrovial
According to research by an international team of scientists testosterone could recharge the sex lives of older women.
New research has found that testosterone patches can significantly increase the sex drive of postmenopausal women not on hormone replacement therapy.
The study, led by Professor Susan Davis from Monash University is the first research which has demonstrated that testosterone alone in the form of a skin patch can significantly improve the sexual well-being of postmenopausal women.
Dr. Davis, a Professor of Women’s Health at Monash’s Department of Medicine says many women after menopause experience a loss of sexual interest and in many instances they seek medical treatment.
Dr. Davis says a number of studies have shown that treatment with testosterone improves sexual well-being in postmenopausal women using oestrogen therapy, but many women do not want to take oestrogen and she says they have found that treatment with a patch which delivers 300 micrograms (ug) of testosterone each day offers a significant improvement in sexual function in postmenopausal women with low libido who are using no other hormone therapy.
The study involved 814 postmenopausal women from 65 centres in the United States, Canada, Australia, the United Kingdom and Sweden and participants were selected at random to receive either a patch delivering 300ug of testosterone daily or a placebo.
At the start of the study the women reported that approximately 50% of all sexual episodes were satisfying but by 24 weeks the group receiving the 300ug testosterone patch reported on average an increase of 2.1 extra satisfying sexual episodes per month compared to an increase of 0.7 in the placebo group - the treatment effects did not differ between naturally and surgically menopausal women and there were few side effects.
Professor Davis says women often worry about the side effects of using testosterone but it is important to note that testosterone is an essential female hormone and premenopausal women normally have much more testosterone circulating in their blood at any given moment than oestrogen.
Professor Davis says more research is being conducted to confirm the safety of testosterone therapy in greater numbers of women over a longer period of time.
At present testosterone therapy is not approved for use in women in Australia.
The study was funded by by Procter and Gamble Pharmaceuticals USA and is published in the New England Journal of Medicine.
An international study showed testosterone, when used with no other hormone therapy, is an effective treatment for low libido in postmenopausal women. More than 800 women from 65 centers in the United States, Canada, Australia, the United Kingdom and Sweden participated in the study, the first to show that testosterone administered by a skin patch
Full Post: Testosterone effective treatment for low libido in postmenopausal women
Every day we all lose thousands and thousands of scalp hairs – men and women. New follicles grow in their place all the time so we don’t notice this hair loss, unless you are going bald. If this is the case, you are probably a man in the 25-40 year age group. Baldness affects men more
Full Post: Propecia is one such drug that has proved to be very successful in treating male baldness
Testosterone therapy may not be the magic bullet women with low libidos are hoping for, according to seasoned sex therapist Domeena Renshaw, MD. “Female sexual dysfunction is being treated as a medical problem with a quick fix, when in fact women’s libido issues may be more complicated,” said Renshaw, author, Seven Weeks to Better Sex,
Full Post: Female testosterone therapy no magic bullet for sexual dysfunction
More than 95 per cent of men who took degarelix for prostate cancer saw their testosterone levels fall dramatically as early as three days after they started treatment, according to a paper in the December issue of BJU International. They also experienced much greater falls in their prostate-specific antigen (PSA) levels at 14 and 28
Full Post: Degarelix prostate cancer drug makes testosterone levels fall dramatically and quickly
The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer. Degarelix is intended to treat patients with advanced prostate cancer. It belongs to a class of agents called gonadotropin releasing hormone (GnRH) receptor inhibitors. These agents slow the growth and progression of
Full Post: FDA approves injectable drug degarelix for advanced prostate cancer